Anixa Biosciences, Inc. (ANIX)

Market Cap	97.99M
Revenue (ttm)	n/a
Net Income (ttm)	-12.36M
Shares Out	32.18M
EPS (ttm)	-0.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,733
Open	3.120
Previous Close	3.120
Day's Range	3.020 - 3.190
52-Week Range	2.150 - 5.130
Beta	0.85
Analysts	Strong Buy
Price Target	8.50 (+179.15%)
Earnings Date	Jan 14, 2025

About ANIX

Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – primarily triple negative breast cancer (TNBC), the letha...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 1, 1987
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: ANIX
• Website: https://www.anixa.com

Analyst Forecast

According to 2 analysts, the average rating for ANIX stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 179.15% from the latest price.

Price Target

$8.5

(179.15% upside)

Analyst Consensus: Strong Buy